Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The restoration of p53 tumor suppressor function is a promising therapeutic strategy to combat cancer. However, the biological outcomes of p53 activation, ranging from the promotion of growth arrest to the induction of cell death, are hard to predict, which limits the clinical application of p53-based therapies. In the present study, we performed an integrated analysis of genome-wide short hairpin RNA screen and gene expression data and uncovered a previously unrecognized role of Sp1 as a central modulator of the transcriptional response induced by p53 that leads to robust induction of apoptosis. Sp1 is indispensable for the pro-apoptotic transcriptional repression by p53, but not for the induction of pro-apoptotic genes. Furthermore, the p53-dependent pro-apoptotic transcriptional repression required the co-binding of Sp1 to p53 target genes. Our results also highlight that Sp1 shares with p53 a common regulator, MDM2, which targets Sp1 for proteasomal degradation. This uncovers a new mechanism of the tight control of apoptosis in cells. Our study advances the understanding of the molecular basis of p53-mediated apoptosis and implicates Sp1 as one of its key modulators. We found that small molecules reactivating p53 can differentially modulate Sp1, thus providing insights into how to manipulate p53 response in a controlled way.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STRING v9.1: protein-protein interaction networks, with increased coverage and integration
Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., Lin, J., Minguez, P., Bork, P., von Mering, C., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1094 · Cited by 4,398 · cited 2×
“Pathway analysis was performed with DAVID (gene-enrichment analysis using EASE score, a modified Fisher exact P-value, as threshold).32 ChIP-seq data were analyzed with a web-based tool, Galaxy.33 Functional protein network analysis was performed with STRING.34 Putative binding sites of Sp1 were predicted using oPOSSU…”
MethodBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“It is well established that the induction of pro-apoptotic genes (that is, Puma, Noxa etc) is required for the initiation of apoptosis by p53.(5,6) However, p53 activated by the MDM2 inhibitor nutlin, in spite of the induction of pro-apoptotic Puma and Noxa, induces cell cycle arrest in a number of cancer lines, with…”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Ilić, D., Almeida, E. A. C., Schlaepfer, D. D., Dazin, P., Aizawa, S., & Damsky, C. H. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.2.547 · Cited by 495
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
Sullivan, K. D., Padilla-Just, N., Henry, R. E., Porter, C. C., Kim, J., Tentler, J. J., Eckhardt, S. G., Tan, A. C., DeGregori, J., & Espinosa, J. M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.965 · Cited by 67 · cited 2×
“screen using pooled siRNA or short hairpin RNA (shRNA) libraries facilitates the understanding of p53-mediated cell cycle arrest.(7,16,17) In the present study, using genome-wide shRNA screen integrated with transcriptomic and chromatin”
BackgroundMethod
Research works printed but not linked: 25
- Selivanova G . Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 2010; 20: 46–56. · DOI
- Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL et al. p53 efficiently suppresses tumor development in the complete absence of its cell cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 2013; 3: 1339–1345. · DOI · Paper page
- Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15: 441–453. · DOI
- Xiong L, Kou F, Yang Y, Wu J . A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop. J Cell Biol 2007; 178: 995–1007. · DOI
- Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A, Li H et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem 2011; 286: 41600–41615. · DOI · Paper page
- Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ 2012; 19: 1992–2002. · DOI · Paper page
- Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010; 70: 5807–5817. · DOI · Paper page
- Bocangel D, Sengupta S, Mitra S, Bhakat KK . p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res 2009; 29: 3741–3750.
- Gualberto A, Baldwin AS Jr . p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem 1995; 270: 19680–19683. · DOI · Paper page
- Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428: 431–437. · DOI · Paper page
- Brummelkamp TR, Fabius AW, Mullenders J, Madiredjo M, Velds A, Kerkhoven RM et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2: 202–206. · DOI · Paper page
- Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2: 474–479. · DOI · Paper page
- Hilton TL, Li Y, Dunphy EL, Wang EH . TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 promoter. Mol Cell Biol 2005; 25: 4321–4332. · DOI
- Grinstein E, Jundt F, Weinert I, Wernet P, Royer HD . Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 2002; 21: 1485–1492. · DOI
- Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G . MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15: 171–183. · DOI · Paper page
- Pećina-Slaus N . Wnt signal transduction pathway and apoptosis: a review. Cancer Cell Int 2010; 10: 22. · DOI · Paper page
- Zeng L, Rowland RG, Lele SM, Kyprianou N . Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 2004; 35: 290–297. · doi:10.1016/j.humpath.2003.11.001
- Brown L, Benchimol S . The involvement of MAPK signaling pathways in determining the cellular response to p53 activation: cell cycle arrest or apoptosis. J Biol Chem 2006; 281: 3832–3840. · DOI
- van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2012; 10: 1590–1598. · DOI · Paper page
- Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G et al. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs Nutlin-3 and RITA. Cancer Res 2009; 69: 6241–6248. · DOI
- Ferlini C, Scambia G . Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange. Nat Protoc 2007; 2: 3111–3114. · DOI
- Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A et al. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 2011; 10: 3346–3358. · DOI · Paper page
- Huang DW, Sherman BT, Lempicki RA . Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 2009; 4: 44–57. · DOI · Paper page
- Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M et al. Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol 2010; Chapter 19: Unit 19.10.1-21.
- Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP et al. oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res 2005; 33: 3154–3164. · DOI · Paper page
Cited by
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Sp1 transcription factor: A long-standing target in cancer chemotherapy
Vizcaíno, C., Mansilla, S., & Portugal, J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.008 · Cited by 377
Esposito, R., Bosch, N., Lanzós, A., Polidori, T., Pulido-Quetglas, C., & Johnson, R. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.019 · Cited by 219
DNA repair and aging: The impact of the p53 family
Nicolai, S., Rossi, A., Di Daniele, N., Melino, G., Annicchiarico-Petruzzelli, M., & Raschellà, G. (2015) · Aging · doi:10.18632/aging.100858 · Cited by 118
“The most investigated biological function of p53 and its family members is doubtlessly apoptosis control [160].”
Background
Metadata
- Authors
- Li, H., Zhang, Y., Ströse, A., Tedesco, D., Gurova, K., & Selivanova, G.
- Venue
- Cell Death & Differentiation
- Published
- 2014-06-27
- Volume
- 21
- Issue
- 9
- Pages
- 1493-1502
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2091392106
- Cited by
- 66
- References
- 10
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by-nc-nd/3.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. https://app.cochat.ai/papers/10.1038/cdd.2014.69
- The paper
- Li, H., Zhang, Y., Ströse, A., Tedesco, D., Gurova, K., & Selivanova, G. (2014). Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. Cell Death & Differentiation. https://doi.org/10.1038/cdd.2014.69
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.